{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:20:46Z","timestamp":1793409646609,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Follicular dendritic cell sarcoma (FDCS) is a rare, low- to intermediate-grade malignancy arising from mesenchymal-derived follicular dendritic cells, which can also present with high-grade pathological features and may rapidly become fatal. Conventional therapeutic strategies, primarily consisting of surgical resection with adjunctive systemic chemotherapy, such as gemcitabine-docetaxel, ifosfamide, doxorubicin, or other regimens, remain inconsistently effective, with median survival notably reduced in advanced or recurrent disease. Given the limited therapeutic options and frequent relapse, there is a critical need for well-tolerated treatments that can improve long-term outcomes for patients with metastatic FDCS. Here, we report the first documented clinical use of the immunomodulatory agent lenalidomide (Revlimid) as maintenance therapy for FDCS following chemotherapy. Remarkably, the patient achieved nearly total sustained remission with exceptional disease stabilization for approximately seven years, experiencing only one manageable recurrence. This clinical response points to lenalidomide as a promising maintenance therapy for metastatic FDCS and may provide further basis for consideration of lenalidomide as a refractory treatment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1801801","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:29:52Z","timestamp":1778732992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Saarang","family":"Kashyap","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha","family":"Sankhala","sequence":"additional","affiliation":[{"name":"University of Queensland","place":["Brisbane, QLD, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Precision Next Gen Oncology and Research Center","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Godin","sequence":"additional","affiliation":[{"name":"Precision Next Gen Oncology and Research Center","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Physiological Science, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Heeter","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Rosant","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh K.","family":"Sankhala","sequence":"additional","affiliation":[{"name":"Department of Biology, University of California, Los Angeles","place":["Los Angeles, CA, United States"]},{"name":"Internal Medicine (IM) Hematology Oncology, Cedars Sinai Medical Center","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20857","article-title":"Dendritic cell neoplasms: an overview","volume":"82","author":"Kairouz","year":"2007","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14672","article-title":"Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma","volume":"178","author":"Jain","year":"2017","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12443","article-title":"Clinicopathological characteristics of extranodal follicular dendritic cell sarcoma: a report of two cases","volume":"21","author":"Zhao","year":"2021","journal-title":"Oncol Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.ijc_944_20","article-title":"Histopathological and immunohistochemical clues to the illusive diagnosis of follicular dendritic cell sarcoma: a clinicopathological masquerader","volume":"59","author":"Sood","year":"2022","journal-title":"Indian J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-025-01614-5","article-title":"Description of two cases of follicular dendritic cell sarcoma, including next-generation sequencing analysis","volume":"20","author":"Jing","year":"2025","journal-title":"Diagn Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2364","article-title":"Follicular dendritic cell sarcoma treated with a variety of chemotherapy","volume":"35","author":"Sasaki","year":"2017","journal-title":"Hematological Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14864","article-title":"Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing","volume":"8","author":"Lorenzi","year":"2017","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228653","article-title":"Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20852","article-title":"Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature","volume":"82","author":"Soriano","year":"2007","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.05.006","article-title":"Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series","volume":"88","author":"Saygin","year":"2013","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24115","article-title":"Follicular dendritic cell sarcoma of the head and neck: case report, literature review, and pooled analysis of 97 cases","volume":"38","author":"Pang","year":"2016","journal-title":"Head Neck"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (review)","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28386","article-title":"Novel insights into the mechanism of action of lenalidomide","volume":"3","author":"Semeraro","year":"2014","journal-title":"OncoImmunology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/dc.25371","article-title":"Cytological diagnosis of follicular dendritic cell sarcoma with a unique pattern of D2\u201040 immunoexpression","volume":"52","author":"Emechebe","year":"2024","journal-title":"Diagn Cytopathol"},{"key":"B16","article-title":"Podoplanin (d2-40): a new immunohistochemical marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas","volume":"1","author":"Xie","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1179554919844531","article-title":"Follicular dendritic cell sarcoma or not? a series of 5 diagnostically challenging cases","volume":"13","author":"Lopez-Hisijos","year":"2019","journal-title":"Clin Med Insights: Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/pai.0b013e318224a5ce","article-title":"Follicular dendritic cell sarcoma of the head and neck expressing thyroid transcription factor-1: a case report with clinicopathologic and immunohistochemical literature review","volume":"22","author":"Jabbour","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1093\/ajcp\/aqab191.178","article-title":"A challenging and rare case of metastatic follicular dendritic cell sarcoma originating from a tonsil","volume":"156","author":"Gallardo","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17122055","article-title":"Current perspectives on mesenchymal dendritic cell neoplasms of lymphoid tissue: insights into ontogeny, updates on classification, and clinicopathologic characteristics","volume":"17","author":"Seth","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-331","article-title":"Follicular dendritic cell sarcoma","volume":"113","author":"Facchetti","year":"2021","journal-title":"Pathologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3560","article-title":"Metastatic follicular dendritic cell sarcoma treated with gemcitabine plus docetaxel with an outstanding survival: a case report and review of literature","volume":"9","author":"Esmati","year":"2020","journal-title":"Clin Case Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-4-6","article-title":"Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review","volume":"4","author":"Conry","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.htct.2024.04.021","article-title":"Two follicular dendritic cell sarcoma (FDCS) patients treated with chemoimmunotherapy","volume":"46","author":"Sahin","year":"2024","journal-title":"Hematology Transfusion Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.816903","article-title":"Response of tonsil follicular dendritic cell sarcoma to multimodal treatment including pembrolizumab: a case report and literature review","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological Malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/s1470-2045(18)30764-2","article-title":"Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma","volume":"20","author":"Mateos","year":"2019","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0440","article-title":"FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01381-1","article-title":"Lenalidomide: a review in previously treated follicular lymphoma","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123021","article-title":"Pitfalls in the diagnosis of nodular lymphocyte predominant hodgkin lymphoma: variant patterns, borderlines and mimics","volume":"13","author":"Younes","year":"2021","journal-title":"Cancers"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140962","article-title":"Follicular lymphomas and histiocytic\/dendritic neoplasms related","volume":"111","author":"Said","year":"2008","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-019-1659-8","article-title":"Divergent immunohistochemical expression of CD21 and CD23 by follicular dendritic cells with increasing grade of follicular lymphoma","volume":"17","author":"Kurshumliu","year":"2019","journal-title":"World J Surg Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1801801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:30:03Z","timestamp":1778733003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1801801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1801801"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1801801","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1801801"}}